Myxedema coma.
Myxedema coma is the term given to the most severe presentation of profound hypothyroidism and is often fatal in spite of therapy. Decompensation of the hypothyroid patient into a coma may be precipitated by a number of drugs, systemic illnesses (eg, pneumonia), and other causes. It typically presents in older women in the winter months and is associated with signs of hypothyroidism, hypothermia, hyponatremia, hypercarbia, and hypoxemia. Treatment must be initiated promptly in an intensive care unit setting. Although thyroid hormone therapy is critical to survival, it remains uncertain whether it should be administered as thyroxine, triiodothyronine, or both. Adjunctive measures, such as ventilation, warming, fluids, antibiotics, pressors, and corticosteroids, may be essential for survival.
Wartofsky
Leonard
L
Department of Medicine, Washington Hospital Center, Washington, DC 20010-2975, USA. leonard.wartofsky@medstar.net
D000368:Aged; D003128:Coma / Q000097:blood / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007010:Hyponatremia / Q000628:therapy; D007022:Hypotension / Q000628:therapy; D007035:Hypothermia / Q000628:therapy; D008297:Male; D009230:Myxedema / Q000097:blood / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000627:therapeutic use
D005938:Glucocorticoids; D013972:Thyrotropin; D013974:Thyroxine